vTv Therapeutics
VTVT
23 hedge funds and large institutions have $2.75M invested in vTv Therapeutics in 2022 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 3 increasing their positions, 7 reducing their positions, and 6 closing their positions.
0.06% less ownership
Funds ownership: 0.19% → 0.14% (-0.06%)
4% less funds holding
Funds holding: 24 → 23 (-1)
17% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 6
27% less capital invested
Capital invested by funds: $3.76M → $2.75M (-$1.01M)
57% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$96.3K |
| 2 |
Prudential Financial
Newark,
New Jersey
|
+$25.6K |
| 3 |
VF
Virtu Financial
New York
|
+$24.7K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$23.9K |
| 5 |
SQA
Simon Quick Advisors
Morristown,
New Jersey
|
+$19.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IC
Ikarian Capital
Dallas,
Texas
|
-$536K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$526K |
| 3 |
CIM
CIM Investment Management
Pittsburgh,
Pennsylvania
|
-$115K |
| 4 |
BFM
Boothbay Fund Management
New York
|
-$56K |
| 5 |
BlackRock
New York
|
-$35.7K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Renaissance Technologies
New York
| – | -$8K | -286 | Closed |
|
|
TRCT
27
Tower Research Capital (TRC)
New York
| – | -$6K | -195 | Closed |
|
28
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$26 | -1 | -25% |
|
29
Fidelity Investments
Boston,
Massachusetts
| – | +$385 | +15 | New |
|
VTVT Hedge Fund Activity: Q2 2022 in Review
23 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in vTv Therapeutics (VTVT) for Q2 2022, worth a combined $2.75M — down 27% from $3.76M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of VTVT and 5 opened new positions — a net loss of 1 holder — while 7 trimmed existing stakes and 3 added.
The largest buyer was State Street, adding an estimated $96.3K. The largest seller was Ikarian Capital, exiting entirely with an estimated $536K sold.
- 23 institutional investors held vTv Therapeutics (VTVT) as of Q2 2022, down from 24 in Q1 2022.
- Funds reported $2.75M of vTv Therapeutics stock for Q2 2022, down 27% quarter-over-quarter.
- 5 funds opened new vTv Therapeutics positions in Q2 2022 and 6 closed out, a net change of -1 holder.
- The largest vTv Therapeutics buyer in Q2 2022 was State Street, an estimated $96.3K added.
- The largest vTv Therapeutics seller in Q2 2022 was Ikarian Capital, an estimated $536K sold.
Based on aggregated 13F filings for Q2 2022.